Press Release
April 13, 2021

Repertoire Completes $189 Million Series B

The Life Sciences team advised Repertoire Immune Medicines in the completion of its $189 million Series B financing. Joining Flagship Pioneering, Repertoire’s institutional founder and principal backer, are new and existing investors including Softbank Vision Fund 2i, the Public Sector Pension Investment Board (PSP Investments), the Alaska Permanent Fund, Invus, and others.

Proceeds from the financing will support the company's further expansion of its proprietary DECODE discovery platform, accelerate its clinical and preclinical pipeline, expand Repertoire’s team, and enhance its manufacturing capabilities.

Repertoire is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune disorders, infectious diseases, and other serious diseases.

The Goodwin team was led by Stuart Cable, Stephanie Richards, Paul Jin, Kathryn Weston and Owen Remeika.

For additional details on the financing, please read the press release and coverage in Endpoints News.